peptide mapping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-26. Anything still debated is marked as such rather than presented as settled.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
=== Novel polymerases === Neither the XNA nor the unnatural bases are recognized by natural polymerases. One of the major challenges is to find or create novel types of polymerases that will be able to replicate these new-to-nature constructs. In one case a modified variant of the HIV-reverse transcriptase was found to be able to PCR-amplify an oligonucleotide containing a third type base pair. Pinheiro et al. (2012) demonstrated that the method of polymerase evolution and design successfully led to the storage and recovery of genetic information (of less than 100bp length) from six alternative genetic polymers based on simple nucleic acid architectures not found in nature, xeno nucleic acids.
=== Standardization for Europe === DVB approved the Standard TS 101 154 V2.1.1, published (07/2014) in the DVB Blue Book A157 Specification for the use of Video and Audio Coding in Broadcasting Applications based on the MPEG-2 Transport Stream, which was published by ETSI in the following months.
=== In traditional societies === Fragments of Nolina species have been recovered from various archaeological sites, though their remains haven't been identified to species level. For example, basketry fragments from caves in western Texas, as well as Nolina remains from various other archaeological sites throughout the greater part of the dry Southwestern United States, have been found. Nolina lindheimeriana contains rotenone, which in many societies has been used as fish poison when fishing for food, and as an insecticide. However, it's been documented that Nolina microcara flowering stalks were cooked on open coals for half an hour, peeled and eaten by the Western Apache people. It's known that rotenone is degraded by high heat.
Sources: en.wikipedia.org
The analysis done based on satellite measurement data, estimates δD for the air in various parts of the world. The general trend is that δD is more negative at higher latitude, so air above Antarctica and the Arctic is D-depleted to around −230‰ to −260‰ or even lower. The estimated atmospheric δDs are shown on the map. A vast portion of global atmospheric water vapor comes from the Western Pacific near the tropics, (mean 2009) and the HIC of air depends on temperature and humidity. Hot, humid regions generally have higher δD. Water vapor in the air is in general more depleted than terrestrial water sources, since 1H216O evaporates faster than 1H2H16O due to higher vapor pressure. On the other hand, rain water is in general more enriched than atmospheric water vapor.
==== Ferrous iron uptake via protein transporters in land plants and chlorophytes ==== Distant homologues of the metal ion transporters ZIP in land plants and chlorophytes have converged in structure, likely to take up Fe2+ efficiently. The IRT1 proteins from Arabidopsis thaliana and rice have extremely different amino acid sequences from Chlamydomonas's IRT1, but their three-dimensional structures are similar, suggesting convergent evolution.
Kimon Georgiev established the political circle "Zveno" with Damyan Velchev in 1927, firstly as a non-partisan organization that aims to improve the socio-political climate in the country. It proclaimed its support for authoritarian power, raised above the strictly party interests, with national purpose. The fascists influence on the Zveno is undisputed, but its not characterized as fascist, but a corporate statism in which it mainly drew inspiration from Italian fascism. Georgiev ceased ties with the Democratic Alliance in 1930 and after the 1931 Bulgarian parliamentary election, he was no longer a deputy of his group. He became a leader of the Zveno and in the beginning of 1932, a newspaper Izgrev was published with one of the editors being Georgiev himself. He published articles in which he criticized communism and the Soviet Union, as well as declaring for a strong government "in the name of order and state intervention in economic life." The primary component of Zveno's ideology was anti-communism, which embraced strong "supra-party" authoritarian bourgeois power of the fascist variety while rejecting the bourgeois democratic system of governance. The bulk of Zveno members joined Aleksander Tsankov's Popular Social Movement in January 1934, but a smaller group led by Kimon Georgiev kept the group operating independently. Zveno was a little organization with little social interaction. It made touch with the Military League, which was once more planning a violent change of government.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.